Cohort of patients for single-cell RNA sequencing of BM cells
| Sample ID . | Origin . | Age, sex . | WHO 2017 . | Karyotype . | Molecular genetics . | % BM blasts . | Previous treatment . | Number of cells . |
|---|---|---|---|---|---|---|---|---|
| HY1 | Femur | 30, M | 651 | |||||
| HY2 | Femur | 65, M | 1558 | |||||
| HY3 | Femur | 55, F | 4190 | |||||
| HY4 | Femur | 70, F | 1050 | |||||
| HY5 | Femur | 52, F | 1576 | |||||
| HY6 | Femur | 90, F | 2031 | |||||
| HY7 | BM | 72, F | 524 | |||||
| MDS1 | BM | 81, M | MDS-MLD | 46,XY [20] | ASXL1, TET2 | <1% | Naive | 481 |
| MDS2 | Femur | 75, F | del5q | 46,XX,del(5)(q13q31), inv(6)(p23q13)[3]/46,XX,del(5)(q13q31),der(11)t(11;17)(q23;p13) [3] | None | 15% | Len, 5Aza | 5422 |
| MDS3 | BM | 79, M | del5q | 46,XY,del(5)(q14q34) [19] 46,XY,del(5)(q14q34), t(7;9)(q21;q34)[3] | TP53 | <5% | Len | 1636 |
| MDS4 | Femur | 86, M | MDS-MLD | 46,XY,del(9)(q13q22) [11] | None | <5% | Naive | 1348 |
| MDS5 | BM | 78, M | MDS-MLD | 46,XY[20] | SF3B1, RUNX1 | <5% | 5Aza | 400 |
| MDS6 | BM | 56, M | MDS-RS-T | 46, XY, del (5)(q14), der(11)t(11;16) (q22;q12),der(16) t(11;16) (q23;p13) t(5;16)(q14;q12)[16] | SF3B1 | <5% | Naive | 418 |
| MDS7 | BM | 67, F | MDS-MLD-RS | 46,XX [20] | SF3B1 | <5% | Naive | 1383 |
| MDS8 | BM | 83, M | MDS-MLD | 46,XY[20] | RUNX1, BCOR | 10% | 5Aza | 1703 |
| Sample ID . | Origin . | Age, sex . | WHO 2017 . | Karyotype . | Molecular genetics . | % BM blasts . | Previous treatment . | Number of cells . |
|---|---|---|---|---|---|---|---|---|
| HY1 | Femur | 30, M | 651 | |||||
| HY2 | Femur | 65, M | 1558 | |||||
| HY3 | Femur | 55, F | 4190 | |||||
| HY4 | Femur | 70, F | 1050 | |||||
| HY5 | Femur | 52, F | 1576 | |||||
| HY6 | Femur | 90, F | 2031 | |||||
| HY7 | BM | 72, F | 524 | |||||
| MDS1 | BM | 81, M | MDS-MLD | 46,XY [20] | ASXL1, TET2 | <1% | Naive | 481 |
| MDS2 | Femur | 75, F | del5q | 46,XX,del(5)(q13q31), inv(6)(p23q13)[3]/46,XX,del(5)(q13q31),der(11)t(11;17)(q23;p13) [3] | None | 15% | Len, 5Aza | 5422 |
| MDS3 | BM | 79, M | del5q | 46,XY,del(5)(q14q34) [19] 46,XY,del(5)(q14q34), t(7;9)(q21;q34)[3] | TP53 | <5% | Len | 1636 |
| MDS4 | Femur | 86, M | MDS-MLD | 46,XY,del(9)(q13q22) [11] | None | <5% | Naive | 1348 |
| MDS5 | BM | 78, M | MDS-MLD | 46,XY[20] | SF3B1, RUNX1 | <5% | 5Aza | 400 |
| MDS6 | BM | 56, M | MDS-RS-T | 46, XY, del (5)(q14), der(11)t(11;16) (q22;q12),der(16) t(11;16) (q23;p13) t(5;16)(q14;q12)[16] | SF3B1 | <5% | Naive | 418 |
| MDS7 | BM | 67, F | MDS-MLD-RS | 46,XX [20] | SF3B1 | <5% | Naive | 1383 |
| MDS8 | BM | 83, M | MDS-MLD | 46,XY[20] | RUNX1, BCOR | 10% | 5Aza | 1703 |
5Aza, azacytidine; F, female; Len, lenalidomide; M, male; WHO, World Health Organization.